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ABSTRACT
Although stem cell transplantation (SCT) is being used for hematopoietic reconstitution following high-dose
chemotherapy for malignancy, it involves certain serious transplant-related complications such as graft-ver-
sus-host disease (GVHD). Angiopoietins play important roles in angiogenesis. However, the role of angiopoie-
tins after SCT is poorly understood. In this study, 52 patients underwent SCT; 26 patients received allogeneic
SCT, while the remaining 26 received autologous SCT. In 48 of 52 patients, levels of angiopoietins, cytokines,
and soluble factors were measured by enzyme-linked immunosorbent assay. Soluble Fas ligand (sFasL) and
endothelial cell-derived microparticle (EDMP) exhibited significant elevation in the early phase (2-3 weeks)
after SCT. In addition, the elevation of interleukin (IL)-6, tumor necrosis factor (TNF)-a, and sIL-2 receptor
(sIL-2R), which are GVHD markers after allogeneic SCT was observed. The level of angiopoietin (Ang)-2 in
allogeneic SCT continued to increase for up to 4 weeks, although the level of Ang-1 did not show significant
changes. The patients with high Ang-2 exhibited significant increase of sFasL and EDMP compared with those
with low Ang-2. In addition, the patients with high-grade GVHD exhibited a significant increase in Ang-2
compared to patients with low-grade GVHD. In the in vitro experiment using endothelial cells, the suppressive
effect of Ang-1 on EDMP generation by TNF-a was partially inhibited by the addition of Ang-2. Furthermore,
multivariate regression analysis showed that EDMP and sFasL were significant factors in Ang-2 elevation. Our
results suggest that Ang-2 generation after allogeneic SCT relates to GVHD.
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Although stem cell transplantation (SCT) is being
used for hematopoietic reconstitution following high-
dose chemotherapy for malignancy, it involves some
serious transplant-related complications [1,2]. For
example, graft-versus-host disease (GVHD), and
vascular disorders, such as veno-occlusive disease, pul-
monary vasculopathy, thrombotic microangiopathy
(TMA), and capillary leak syndrome [3-5]. Although
the complex pathophysiology of acute GVHD
(aGVHD) involves the conditioning regimen,
cytokines, nitric oxide, and non-T effector cells, the
cytolytic activity of donor T cells is essential for the766development of GVHD activity [6,7]. The cytolytic
activity of cytotoxic T-lymphocyte (CTL) is primarily
mediated through certain effector mechanisms such as
the Fas/Fas ligand (FasL) and perforin/granzyme
pathways [8,9]. Interaction of FasL, expressed on the
CTL cell surface, with the Fas receptor on the target
cell membrane results in the initiation of the Fas cell
death pathway [10]. Recent accumulating evidence
indicates that the Fas/FasL system is implicated in
the pathogenesis of aGVHD [7,11-13].
Cellular microparticles are fragments that shed
almost spontaneously from the plasma membrane
blebs of virtually all cell types when subjected to
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these microparticles have more recently been shown
to reflect in vitro cell stimulation, and testify to cellular
activation and/or tissue degeneration occurring in vivo
under various pathophysiologic conditions [14,15].
Thus, there is a possibility that the cellular micropar-
ticles exhibit a dynamic change after SCT [16]. In con-
trast, diagnosing vascular complications in patients
undergoing SCT is challenging, and damage to endo-
thelial cells is regarded as the common feature of these
complications [17,18]. Furthermore, endothelial
damage, perpetuated by CD81 CTL, has been linked
to GVHD, which is described in the skin and gut
[18-22].
Angiopoietin-1 (Ang-1) is a ligand of the endothe-
lial-specific tyrosine-kinese receptor Tie2, and is an
essential mediator of angiogenesis [23-25]. Ang-1 is
also an endothelial survival factor [26], and was re-
cently shown to protect blood vessels against plasma
leakage in vivo and to inhibit endothelial permeability
in vitro [27-29]. As well, Ang-1 inhibits leukocyte
adhesion to vascular endothelium and reduces the
expression of tissue factor and various adhesion mole-
cules in endothelial cells stimulated by inflammatory
cytokines [29-32]. Ang-2, on the other hand, has
been proposed as a natural antagonist of Ang-1, pro-
moting an apoptosis of endothelial cell. Thus, angio-
poietins play an important role in a neovasculization
and endothelial abnormalities [33-35]. However, the
role of angiopoietins after SCT is poorly understood.
We measured and compared levels of angiopoie-
tins, cytokines, and soluble factors in patients under-
going SCT. The results suggested that angiopoietins
play a unique role after SCT.
MATERIALS AND METHODS
Patients
The subjects were 52 patients who underwent
SCT between August 2001 and June 2007 at the insti-
tution of residence. In all, 26 patients received alloge-
neic SCT, whereas the remaining 26 received
autologous SCT (Table 1). The 12 male and 14 female
allogeneic SCT patients ranged in age from 6 to 70
years (median: 32 years), and the 14male and 12 female
autologous SCT patients ranged in age from 36 to
71 years (median: 53 years). Patient diagnoses con-
sisted of 7 acute myeloid leukemia, 3 acute promyelo-
cytic leukemia, 6 acute lymphoblastic leukemia, 2
chronic myeloid leukemia, 5 myelodysplastic syn-
drome, 13 diffuse large B cell lymphoma, 5 follicular
cell lymphoma, 7 multiple myeloma, and 4 others.
Conditioning applied was: total body irradiation
(TBI) for 15 and non-TBI for 37. For allogeneic
SCT, prophylaxis included cyclosporine for 26 pa-
tients with GVHD. The donor sources were 6 bone
marrow transplantations, 12 peripheral blood SCTs,and 8 cord blood transplantations (Table 2). Written
informed consent was obtained from all the patients.
Cytokine Evaluation
Blood samples from patients were collected into
tubes containing sodium citrate or tubes without any
anticoagulant and the blood was allowed to clot at
room temperature for a minimum of 1 hour. Then se-
rum or citrated plasma was isolated by centrifugation
for 20 minutes at 1000  g at 4C. The serum was di-
vided into aliquots and frozen at 230C until use. As
a positive control, recombinant products were used
in each assay, as well as standard solutions provided
with the commercial kits. Human tumor necrosis
factor (TNF)-a, interferon (IFN)-g, interleukin
(IL)-4, and IL-6 ELISA kits were purchased from
BioSource International, Inc. (Camarillo, CA). Serum
levels of cytokines were measured according to the
manufacturer’s instructions. Normal ranges were as
follows: TNF-a: 5-20 pg/mL, IFN-g: 0-12.5 pg/mL,
IL-4: 0-3.5 pg/mL, and IL-6: 0.2-4.5 pg/mL.
Measurement of Soluble (s)FasL, sIL-2 Receptor
(R), sVascular Cell Adhesion Molecule (VCAM)-1,
sE-Selectin, Ang-1, and Ang-2
sFasL, sIL-2R, sVCAM-1, sE-selectin, Ang-1,
and Ang-2 ELISA kits were purchased from
Table 1. Patients and Treatment Characteristics
Allogeneic
SCT
Autologous
SCT
Sex
Male/female 12/14 14/12
Median age (range) 32 (6-70) 53 (36-71)
Patient diagnosis at transplantation
Acute myeloblastic leukemia (AML) 7 0
Acute promyeloblastic leukemia (APL) 3 0
Acute lymphoblastic leukemia (ALL) 6 0
Chronic myeloblastic leukemia (CML) 2 0
Diffuse large B cell lymphoma (DLBC) 1 12
Follicular cell lymphoma (FCL) 0 5
Aplastic anemia (AA) 1 0
Myelodysplastic syndrome (MDS) 5 0
Multiple myeloma (MM) 0 7
Nonhematologic cancer 1 2
Conditioning regimen
TBI-containing 11 4
CY/TBI 6 0
Flu/L-PAM/TBI 5 0
L-PAM/TBI 0 4
Non-TBI-conditioning 15 22
Flu 4 0
Flu/Bu 5 0
Flu/L-PAM 6 0
VP-16/CY 0 5
MCNU/IFO/CBDCA/VP-16 0 10
MCNU/L-PAM/Ara C/VP-16 0 7
TBI indicates total body irradiation; CY, cyclophosphamide; Flu,
fludarabine; Bu, busulfan; L-PAM,melphalan; VP-16, etoposide;
MCNU, ranimustine; IFO, ifosfamide; CBDCA, carboplatin;
Ara C, cytarabine.
768 S. Nomura et al.BioSource International Inc. For measurement of
sFasL, sIL-2R, sVCAM-1, and sE-selectin in serum,
all the kits were used according to the manufac-
turer’s instructions. Normal ranges were as follows:
sFasL: 0.02-0.14 ng/mL, sIL-2R: 150-450 IU/mL,
sVCAM-1: 395-714 ng/mL, sE-selectin: 23.0-79.2
ng/mL, Ang-1: 1.8-13.2 ng/mL, and Ang-2: 1.5-4.6
ng/mL.
Activation of Endothelial Cells
Endothelial cells isolated from freshly obtained
human umbilical cord veins were cultured according
to themethod of Jaffe and colleagues [36]. Second-pas-
sage cells were grown to confluence in 25 cm2 culture
flasks (3-4 days). The cells were subcultured in 12-well
plates containing M-199 with growth supplement,
fetal bovine serum, and heparin, after which they
were washed once with 10 mM EDTA in phosphate-
buffered saline to remove calcium-dependent binding
proteins such as vitamin K-dependent coagulation fac-
tors. EDTA was subsequently removed by 3 washes
with 0.4% fetal bovine serum albumin. Then, the cells
were incubated at 37C with 10 ng/mL of TNF-a (Bi-
oSource International Inc.), 250 ng/mL of Ang-1 or
Ang-2 (R&D Systems, Minneapolis, MN) in M-199,
0.4% BSA. Samples of the cells containing FITC-
labeled anti-annexin V or PE-labeled CD51 were
added to Falcon tubes and analyzed using the Ortho
Cytoron Absolute Analyzer.
Table 2. Allogeneic SCT Outcome
Value
Donor sourse
Related 7
HLA-identical sibling 4
Mismatched family member 2
HLA-matched family member 1
Unrelated 19
HLA-matched 12
Mismatched 7
Stem cell sourse
Bone marrow transplantation (BMT) 6
Peripheral blood
stem cell transplantation (PBSCT)
12
Cord blood transplantation (CBT) 8
Alive/dead 16/10
Cause of death progression 2
Death without progression 6
GVHD 1
Infection 3
TMA 2
Not described 2
GVHD
Acute GVHD 26
Chronic GVHD 7
GVHD indicates graft-versus-host disease; TMA, thrombotic
microangiopathy.Assessment of Endothelial Cell-Derived
Microparticles (EDMPs)
EDMPs were detected using a previously reported
method with somemodifications [37]. A 10-mL aliquot
of washed intact platelets (3  108/mL) was added
to the plasma, and the mixture was incubated for
30 minutes in dark at room temperature, with FITC-
labeled Annexin V (FITC-Ann V) and phycoerythrin
(PE)-labeled CD51 (avb3) to detect EDMP. The sam-
ples were diluted 1:10 with HEPES-Tyrode’s buffer
containing 5 mmol/L EGTA and analyzed using the
Ortho Cytoron Absolute Analyzer (Ortho Diagnostic
Systems, Inc., Tokyo, Japan), set to detect only the
particles bound to FITC-labeled Annexin V and
PE-labeled CD51. This method was designed to en-
sure the detection of only procoagulant EDMP. The
concentrations of these microparticles were then
calculated per microliter of the whole blood.
Statistical Analysis
Results are shown as the mean 6 standard errors.
Variables in the 2 distribution groups were compared
using the Mann-Whitney U-test or t-tests, as appro-
priate. Statistical significance was defined as a 2-tailed
value of P\ .05. The correlation between Ang-2 and
other continuous-response variables was assessed by
univariate and multivariate linear regression analysis.
The disease-free survival (DFS) was calculated from
the date of transplant to the date of relapse or any cause
of death. The survival curves were estimated using the
method of Kaplan and Meier.
RESULTS
SCT-Related Complications
Twenty-six patients who received allogeneic SCT
developed aGVHD (grade I, 11; grade II, 9; grade III,
4; grade IV, 2) (Table 2). Three patients (grade III and
IV) who received allogeneic SCT had severe complica-
tions and died within the first 4 weeks. Another, who
had received autologous SCT, suffered from severe
sepsis and died early. Therefore, 4 patients—3 from
those who received allogeneic SCT and 1who received
autologous SCT—were excluded from the analysis of
the present study.
Changes in Serum Cytokines and Soluble Factors
The level of cytokines and soluble factors before
and after SCT is shown in Table 3. IFN-g levels
were found to be significantly higher 3 weeks after
allogeneic SCT than beforehand, whereas IL-4 and
IFN-g levels after autologous SCT remained almost
unchanged. In contrast, TNF-a, IL-6, sIL-2R,
sVCAM-1, and sE-selectin exhibited a significant
elevation after both autologous and allogeneic SCT,
although the changes after autologous SCT were tem-
porary. Levels of sIL-2R, sVCAM-1, and sE-selectin
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After SCT
Cytokine/Factor Before SCT 1 Week 2 Weeks 3 Weeks 4 Weeks
Allo SCT (n 5 23)a
IFN-g (pg/mL) 9.2 ± 0.5 11.8 ± 0.8 13.4 ± 0.5 14.5 ± 1.2* 14.9 ± 0.9**
IL-4 (pg/mL) 5.4 ± 0.4 5.4 ± 0.7 5.8 ± 0.4 5.8 ± 0.5 5.6 ± 0.5
TNF-a (pg/mL) 12.4 ± 0.8 16.7 ± 1.3 24.5 ± 1.9* 28.5 ± 5.7** 23.9 ± 1.6*
IL-6 (pg/mL) 21.3 ± 6.2 34.7 ± 6.5 51.8 ± 14.2** 49.7 ± 10.1* 47.6 ± 15.1*
sIL-2R (IU/mL) 725 ± 61 757 ± 73 1,033 ± 69* 1,134 ± 52* 1,337 ± 98**
sVCAM-1 (pg/mL) 965 ± 66 1,139 ± 73 1,366 ± 91* 1,579 ± 91** 1,631 ± 123**
sE-selectin (ng/mL) 66.5 ± 3.8 72.2 ± 4.4 90.5 ± 4.7* 118.5 ± 5.5** 128.8 ± 7.2**
Auto SCT (n 5 25)b
IFN-g (pg/mL) 6.4 ± 0.8 6.2 ± 0.7 5.9 ± 0.6 5.8 ± 0.6 6.4 ± 0.8
IL-4 (pg/mL) 3.6 ± 0.5 3.7 ± 0.7 3.5 ± 0.8 3.1 ± 0.7 2.9 ± 0.9
TNF-a (pg/mL) 8.6 ± 1.1 10.2 ± 1.4 14.8 ± 1.9* 10.6 ± 1.2 9.8 ± 0.9
IL-6 (pg/mL) 12.5 ± 2.3 38.8 ± 22.1* 42.8 ± 12.5* 19.8 ± 5.2 15.6 ± 4.4
sIL-2R (IU/mL) 853 ± 148 1,458 ± 361* 1,429 ± 154* 1,170 ± 165 1,039 ± 113
sVCAM-1 (pg/mL) 1217 ± 86 1,165 ± 122 1,449 ± 65* 1,252 ± 97 1,128 ± 120
sE-selectin (ng/mL) 84.6 ± 10.3 79.7 ± 4.6 91.7 ± 10.2* 119.5 ± 13.1* 94.8 ± 9.3
TNF-a indicates tumor necrosis factor a; IFN-g, interferon g; IL-4, interleukin 4; IL-6, interleukin 6; sIL-2R, soluble interleukin-2 receptor;
sVCAM-1, soluble vascular cell adhesion molecule-1; sE-selectin, soluble E-selectin.
*P\ .05; **P\ .01.
aThree patients who had severe complications and died after the procedure were excluded from the analysis of the present study (see ‘‘SCT-
related complications in Results.’’
bOne patient who suffered from severe sepeis was excluded from the analysis of the present study (see ‘‘SCT-related complications in Results,’’
Data represent means 6 standard error.after allogeneic SCT continued to increase for up to
4 weeks.
Changes in sFasL, EDMP, Ang-1, and Ang-2
Figure 1 shows the changes in sFasL, EDMP, Ang-
1, and Ang-2 levels after SCT. The level of sFasL in
the group that received allogeneic SCT peaked within
3 weeks (0.32 6 0.05 ng/mL, P\ .001) and then de-
creased. The level of EDMP showed the same ten-
dency as sFasL (allogeneic SCT: 2 weeks, 491 6 53/
mL, P\ .05; 3 weeks, 595 6 87/mL, P\ .01, 4 weeks,
522 6 59/mL, P\ .05). The level of Ang-2 in alloge-
neic SCT continued to increase for up to 4 weeks
(2 weeks, 3.9 6 0.5 ng/mL, P\ .05; 3 weeks, 4.7 6
0.4 ng/mL, P\ 0.05; 4 weeks, 5.8 6 0.7 ng/mL, P\
.01), although the level of Ang-1 did not show signifi-
cant changes. In contrast, levele of sFasL, EDMP,
Ang-1, and Ang-2 in the recipients of autologous
SCT did not show significant changes. There were
no significant correlations between sFasL, EDMP,
Ang-1, and Ang-2 in the recipients of allogeneic SCT.
Figure 2 shows the changes in levels of sFasL and
EDMP at 4 weeks in the recipients of allogeneic
SCT with elevated Ang-2 levels. sFas and EDMP
levels at 4 weeks in allogeneic SCT with elevated
Ang-2 (greater than the mean 1 2 standard deviations
of basal levels) were used for the analysis. Ten patients
had high Ang-2 levels (Ang-2 .4.5 ng/mL). The pa-
tients with high Ang-2 exhibited significant increaseof sFasL and EDMP compared with those without
high Ang-2.
GVHD, DFS, and Angiopoietins in Patients after
Allogeneic SCT
The actual incidence of high-grade aGVHD
(grade II-IV) was 52.8%. Projected DFS at 1000
days with and without high-grade aGVHD was 0.37
6 0.04 versus 0.786 0.06 (P5 .04; Figure 3). Figure 4
shows the changes in levels of Ang-2 at 4 weeks with
and without high-grade aGVHD in the recipients of
allogeneic SCT. The patients with high-grade
GVHD exhibited significant increases in Ang-2 com-
pared to patients with low-grade GVHD. However,
the DFS at 1000 days exhibited no significant differ-
ences (Figure 5). Table 4 shows the relationship be-
tween Ang-2 and cytokines/soluble factors in
univariate and multivariate regression analysis. Simple
linear regression analysis showed significant correla-
tions that were performed on TNF-a, IL-6, sIL-2R,
sVCAM-1, sE-selectin, sFasL, and EDMP. We loga-
rithmically transformed and calculated all variables.
Before multiple linear regression analysis, we per-
formed Pearson’s product-moment correlation analy-
sis among all relevant variables. In cases where the
correlation coefficients (r) exceeded 0.8 in these vari-
ables, we selected the ones that presented with the
higher b regression coefficient by simple linear regres-
sion analysis. In the multiple linear regression model,
IFN-g, TNF-a, sVCAM-1, sFasL, and EDMP levels
770 S. Nomura et al.Figure 1.Changes of sFasL, EDMP, Ang-1, and Ang-2 in patients undergoing allogeneic and autologous SCT. Blood samples were obtained on
days 0 (basal), 7 (1 weeks), 14 (2 weeks), 21 (3 weeks), and 28 (4 weeks) after the transplantation. Error bars show standard error. Student’s t-test
was used for statistical comparisons.were investigated. EDMP and sFas-L were signifi-
cantly correlated with Ang-2 (Table 4).
Relationship between Ang-1, Ang-2, and EDMP in
Activated Endothelial Cells
Figure 6 shows the release of EDMP from endo-
thelial cells caused by TNF-a and detected by flow
cytometry using FITC-labeled Annexin V and PE-
labeled CD51 (Figure 6A and B). TNF-a promotedthe release of EDMP (Figure 6C) and Ang-1 inhibited
this promotion (Figure 6D). However, this effect
of Ang-1 was partially inhibited by the addition of
Ang-2 (Figure 6E).
DISCUSSION
SCT provides an opportunity to trace the process
of hematopoietic reconstitution in vivo, and manyFigure 2. sFasL and EDMP levels in patients after allogeneic SCT with and without high-Ang-2. Values presented as mean 6 standard error.
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topoiesis. In the present study, several cytokines and
soluble factors were measured. TNF-a, IL-6, sIL-
2R, sVCAM-1, and sE-selectin exhibited a significant
elevation after both autologous and allogeneic SCT,
although the changes after autologous SCT were
temporary. In addition, sFasL and EDMP were mea-
sured before SCT and serially after SCT, and these
factors exhibited a significant elevation in the early
phase (2 or 3 weeks) after SCT (Figure 1). It has pre-
viously been reported that certain cytokines and sol-
uble factors are useful for the diagnosis of GVHD
after allogeneic SCT [38-40]. Proinflammatory cyto-
kines including IFNg, IL-6, and TNF-a are impor-
tant mediators and regulators of GVHD [38,39].
sIL-2R appears to be a convenient marker for the
detection of aGVHD [40]. In the present study, the
Figure 3. Probability of DFS in aGVHD.The estimated probability
of DFS at 2 years was 78% (grade I) and 37% (grade II-IV).
Figure 4. Ang-2 levels in patients after allogeneic SCT with and
without high-grade GVHD. Values presented as mean 6 standard
error.involvement of sFasL in the elevation of IL-6,
TNF-a, and sIL-2R after allogeneic SCT appeared
to be important, because sFasL exhibited the same
changes as these cytokines and soluble factors
[41-43]. EDMP also exhibited changes similar to
those of sFasL. It is reported that EDMP exhibit a dy-
namic change after SCT [16]. In particular, the
increase of EDMP in the TMA/thrombotic throm-
bocytopenic purpura (TTP) case was quite remark-
able [16,44]. Recently, Pihusch et al. [45] reported
that elevation of EDMPs during aGVHD might in-
duce endothelial cell injury after hematopoietic
SCT and might serve as a diagnostic test for early
differentiation of aGVHD from other transplant-
related complications. Thus, our results suggest the
possibility that sFasL and EDMP play a role in
GVHD after allogeneic SCT [11-13,46].
Figure 5. Probability of DFS in relation to Ang-2 levels. The esti-
mated probability of DFS at 2 years was 56% (low-Ang-2) and
44% (high-Ang-2).
Table 4. Relationship between Ang-2 and Cytokines/Soluble Factors in
Multivariate Regression Analysis
Univariate Analysis Multivariate Analysis
Variable R P value P value
IFN-g (pg/mL) 0.038 .456 .634
IL-4 (pg/mL) 0.066 .293
TNF-a (pg/mL) 0.237 \.05 .419
IL-6 (pg/mL) 0.259 \.05
sIL-2R (IU/mL) 0.218 \.05
sVCAM-1 (pg/mL) 0.297 \.01 .184
sE-selectin (ng/mL) 0.231 \.05
sFasL (pg/mL) 0.312 \.01 \.05
EDMP (/mL) 0.358 \.001 \.01
Ang-1 (ng/mL) 0.091 .552
IFN-g indicates interferon g; IL-4, interleukin 4; TNF-a, tumor
necrosis factor a; IL-6, interleukin 6; sIL-2R, soluble interleu-
kin-2 receptor; sVCAM-1, soluble vascular cell adhesion mole-
cule-1; sE-selectin, soluble E-selectin; sFasL, soluble Fas
ligand; EDMP, endothelial cell-derived microparticle; Ang-1,
angiopoietin-1.
772 S. Nomura et al.Figure 6. Flow cytometric analysis of EDMP. Only particles positive for FITC-labeled Annexin V and PE-CD51 were gated to distinguished
endothelial cells and EDMP from electric noise (A, B). EDMPs were elevated by stimulation of TNF-a (C), and this elevation was inhibited the
addition of Ang-1 (D). Furthermore, the suppressive effect of Ang-1 was partially inhibited by the addition of Ang-2 (E).Although many cytokines are known to control the
process of hematopoiesis after SCT, the role of angio-
poietins in this process is not well understood. In the
present study, the level of Ang-2 in allogeneic SCT
continued to increase for up to 4 weeks, although the
level of Ang-1 did not show significant changes. In ad-
dition, the patients with high Ang-2 exhibited signifi-
cant increase of sFasL and EDMP compared with
those without high Ang-2 (Figure 2). To understand
the relationship between Ang-2 and GVHD, we ana-
lyzed the DFS. In the present study, the actual inci-
dence of high-grade aGVHD (grade II-IV) was
52.8%, and projected the DFS at 1000 days with and
without high-grade aGVHD was 0.37 6 0.04 and
0.78 6 0.06, respectively. In addition, the patients
with high-grade GVHD exhibited a significant in-
crease in Ang-2 compared to patients with low-grade
GVHD. Thus, our results suggest the promotional
effect of Ang-2 on GVHD, although the actual DFS
at 1000 days with or without high Ang-2 exhibited
no significant differences. Ang-1, a major physiologi-
cal ligand for Tie2 receptor, is responsible for the
recruitment and stable attachment of pericytes result-
ing in vascular maturation in the process of angiogen-
esis [24]. Ang-1 has been shown to promote
endothelial cell survival without causing proliferation
[47], and to stabilize endothelial interactions with sur-
ronding support cells [27]. It can block the vascular
permeability effects of VEGF in vivo [27,28]. In addi-
tion, the VEGF-induced vascular permeability appears
to be a cause of capillary leak syndrome, which is 1 ofthe transplant-related complications. We previously
reported that platelet activation markers such as
sCD40L, platelet-derived MP and RANTES contin-
ued to increase after allogeneic SCT [48]. In addition,
activated platelets release Ang-1 [49-51].
On the other hand, Ang-2 competitively inhibits
the binding of Ang-1 to Tie2, acting like a natural an-
tagonist and rendering blood vessels ‘‘unstable’’ [52].
Also, it is reported that Ang-2 is rapidly released
upon stimulation from endothelial cell [53]. When en-
dothelial cells are activated after SCT, they could gen-
erate Ang-2. In this manner, Ang-2 generation after
allogeneic SCT makes it possible to promote GVHD
because of the inhibition of Ang-1-related function.
We performed the in vitro experiment using endothe-
lial cells to understand whether Ang-2 plays a patho-
genic role in the endothelial injury, which occurs
during aGVHD. Ang-1 inhibited the release of
EDMP promoted by TNF-a, and this effect of Ang-1
was partially inhibited by the addition of Ang-2. These
results suggest that the increase in Ang-2 promotes the
endothelial injury related to GVHD. Indeed, in the
present study, the multivariate regression analysis
showed that EDMP and sFasL were significant factors
in the elevation of Ang-2. However, our study has
some limitations: it was a small sample size, and
some patients who had severe complications were
excluded from the analysis of the present study. There-
fore, further examination will be necessary to establish
the exact mechanism of Ang-2-related promotion for
GVHD after allogeneic SCT.
Angiopoietins and microparticles after SCT Transplantation 773In conclusion, wemeasured and compared levels of
cytokines and soluble factors in patients undergoing
SCT. Ang-2, sFasL, and EDMP exhibited particular
changes after SCT. Our results suggest that Ang-2
generation after allogeneic SCT relates to the promo-
tion of GVHD.
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